alexion continu exceed expect solid
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
alexion pharmaceut land uniqu ultrarare-diseas
blockbust soliri expand reach
origin approv paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom ahu gener
myasthenia gravi gmg neuromyel optica
spectrum disord nmosd alexion provid
disease-modifi treatment avail indic give
firm substanti price power patient share
potenti expand new indic two drug
ultrarar diseas strensiq kanuma promis pipelin
well-posit retain lead statu rare-diseas market
special salesforc believ alexion
despit outsiz success soliri alexion come
turbul year expens acquisit metabol
indic investig aggress sell tactic
nearli complet manag turnov restructur
program believ alexion final side
seriou misstep execut previou manag
new leadership record larg unprov strong
launch soliri gmg approv ultomiri continu
effort bolster pipelin point new era beleagu
pipelin competit grow drug manufactur flock
lucr autoimmun market alexion first-mov statu
well ultomiri relat pipelin mitig risk
addit firm continu drive growth
identif new patient across globe alexion
special salesforc strong entrench patient
doctor rais barrier entri brand competitor
soliri high price draw question price pressur whether
polit motiv incit mount competit
howev volum growth label expans conveni
dose ultomiri alreadi cheaper soliri
help stave consider price headwind biosimilar
brand competitor encroach indic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria
neuromyel optica spectrum disord nmosd next-gener
ultomiri approv pnh ahu strensiq kanuma target
ultrarar metabol diseas alexion pipelin target rare diseas
high unmet need hematolog nephrolog metabol diseas neurolog
cardiolog area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
alexion continu exceed expect solid
slightli expect solid progress toward
convert soliri patient next-gener ultomiri
continu pipelin expans cost remain within
reason level total third-quart revenu
billion last year adjust oper
margin improv basi point despit
concern brand biosimilar competit think
narrow-moat alexion well posit hold patient
share four rare ultrarar complement-medi
diseas soliri treat addit seen
pipelin flourish thank acquisit collabor
deal provid addit avenu growth
rare diseas adjust manag rais
full-year guidanc maintain fair valu
estim per share
key question face alexion fare
soliri impend biosimilar threat think alexion
result everi quarter support thesi
next-gener ultomiri conveni
dose offer compel reason patient switch
also think mani patient reluct switch
back less-conveni dose biosimilar enter
market oct elig soliri
patient convert ultomiri mark impress
progress toward compani goal convers
progress germani japan addit ultomiri
recent garner approv second indic atyp
hemolyt urem syndrom ahu allow alexion
switch ahu patient well ahead competit
entri think alexion network patient doctor
support futur commerci effort ultomiri
continu garner approv new indic
importantli even alexion focus ultomiri
convers complement franchis soliri
ultomiri continu see new growth thank soliri
continu penetr gener myasthenia gravi
gmg newli approv neuromyel optica spectrum
disord nmosd third-quart revenu soliri
ultomiri total billion last year
expect two drug earn billion revenu
alexion metabol portfolio perform slightli
expect quarter testament compani
educ effort improv awar diagnosi
ultrarar
hypophosphatasia post million sale
last year driven entir volum growth
kanuma ultrarar lysosom acid lipas defici lal-
contribut million third quarter
last year volum last year
increas full-year estim two drug
million line manag new guidanc
expect continu modest contribut set
therapi ultrarar indic
rare ultrarar
alexion pipelin significantli expand sinc last
year compani current clinic candid
cardiolog other includ preclin compani
develop program across sever asset
repres mark improv time last
year firm hand drug candid outsid
complement franchis like compani focu
rare diseas high unmet need new
therapi significantli impact patient live
command strong price power believ focu
could continu support alexion narrow moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
current assign alexion neg moat trend
inform soliri biosimilar threat pleas
see aug note amgen challeng alexion soliri
patent sell-off unwarr ultomiri
inform soliri brand competit
pleas see oct note ucb buy ra pharmaceut
billion challeng alexion soliri myasthenia
inform alexion recent acquisit
achillion well option agreement stealth
biotherapeut pleas see oct note alexion
achillion share under-valued
key driver per share fair valu estim
price volum alexion key drug soliri
ultomiri model steadi revenu growth
driven modest patient growth pnh ahu
dampen slightli push convert patient
ultomiri solid growth gmg approv
success roll-out nmosd approv model
single-digit price headwind soliri ultomiri
probability-weight competitor entri start
biosimilar entri throughout explicit forecast
project assum substanti patient declin pnh
ahu due biosimilar slightli larger hit
outsid howev regulatori orphan drug
exclus newer launch gmg nmosd
also larger address patient popul bolster
alexion posit price headwind off-set volum
increas led gmg nmosd
pipelin contribut million
probability-adjust sale given
believ compani face signific competit
headwind soliri patent expir potenti
entri brand biosimilar competitor howev
see path alexion off-set pipelin
success overal think alexion healthi group
candid sever lucr diseas area variou
stage clinic develop definit
develop call regardless compani
healthi financi posit finish quarter
billion cash equival billion debt
closest catalyst horizon top-lin readout
phase trial danicopan patient paroxysm
hemolysi expect end year anoth
near-term catalyst phase readout stealth
biotherapeut elamipretid primari mitochondri
myopathi pmm expect first quarter next year
remind alexion option co-develop
commerci molecul follow readout
result believ could blockbust
opportun mitochondri diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
candid earli stage posit trial readout
pipelin could provid upsid valuat
strensiq kanuma grow modestli throughout
forecast believ face competitor
given obscur indic result five-year
revenu compound-annual-growth-rate low-single-digit revenu
compound-annual-growth-rate despit continu increas
oper expens fund commerci
revenu growth
end forecast
compani long-term outcom hing factor
includ success convert patient soliri
ultomiri time subcutan version ultomiri
time competitor entri result believ
alexion face rather wide rang possibl outcom
give compani high uncertainti rate
bear case brand competitor biosimilar
larger impact alexion sale competitor
captur outsiz patient share base price safeti
efficaci case alexion face annual
double-digit price headwind ultomiri pipelin
failur result substanti revenu declin
fair valu estim per
bull case brand competitor fail reach approv
impact biosimilar mute thank ultomiri
attract dose schedul price model smaller
price headwind compani see essenti flat
revenu case fair valu
estim per share
ultrarar rare diseas high unmet medic need
ultrarar paroxysm nocturn hemoglobinuria pnh
alexion blockbust drug soliri extend
reach ultrarar atyp hemolyt urem syndrom
ahu rare gener myasthenia gravi
gmg rare neuromyel optica spectrum
disord nmosd soliri patent
protect market exclus pnh ahu set
expir next five year orphan drug exclus
continu provid protect gmg nmosd
larger target popul still fit
compani focu rare life-threaten diseas
ultomiri approv pnh end ahu
offer conveni dose schedul
opportun maintain signific market share
addit patent protect market exclus strensiq
ultrarar hypophosphatasia kanuma
ultrarar lysosom acid lipas defici lal-d
launch pair alexion pipelin
candid rare indic provid diversif
alexion
treatment option
patient autoimmun metabol diseas
target compani drug pipelin
prognos caus diseas slightli differ
patient pnh ahu devast
uncontrol activ immun system specif
part call complement result chronic
destruct red blood cell lead blood clot
organ failur thirty-f percent pnh patient die within
five year ahu patient progress end-stag
renal diseas lal-d patient miss key
enzym critic metabol function case
onset diseas start birth close
birth patient die organ failur within year gmg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
nmosd character unpredict relaps
includ life-threaten symptom like respiratori
failur gmg nmosd well blind
paralysi nmosd access alexion drug
matter life death alexion treat
diagnos popul pnh ahu predict
similar dynam gmg nmosd well
compani focu rare ultrarar diseas well
unmatch efficaci soliri allow alexion
maintain substanti price power line rare-
ultrarare-diseas drug soliri come high price
tag estim annual list net price soliri
pnh
indic meanwhil strensiq
kanuma price nontrivi net annual sum
per patient respect
per-pati cost extrem high overal burden
countri healthcar system small sinc number
affect patient extrem limit drug
clear disease-modifi benefit help justifi high price
facilit reimburs payer public
privat dynam allow alexion maintain
narrow band ex-u price
compani proactiv price ultomiri discount
soliri facilit patient convers new drug
list net price
indic strong patient convers crucial patient
share retent biosimilar competitor enter
pictur concern ultomiri price
discount absolut term drug still fetch
hefti figur even rare-diseas standard also first
year ultomiri includ seri initi load dose
actual put first year ultomiri roughli
premium soliri pnh dynam allow
compani captur valu crucial prebiosimilar
year patient convert maintain drug
cheaper long run
potenti brand competitor hurdl high bar
efficaci conveni establish soliri
ultomiri face signific barrier market entri
given alexion salesforc network patient
doctor mani alexion potenti brand competitor
inject self-administ alexion also
work subcutan form ultomiri
approv could enter market possibl sooner
believ alexion first-to-market statu soliri
strong efficaci ultomiri much conveni
dose schedul six seven infus per year versu
infus per year establish high barrier entri
even competitor succe reach regulatori
approv compet compani would face uphil
battl alexion global network patient
doctor well special salesforc
decad experi ultrarar rare diseas given
averag doctor never encount patient
one rare diseas career take
uniqu strategi identifi educ correct contact
soliri approv countri intang
asset gener alexion decade-plu global
experi rare autoimmun diseas easili
match competitor alexion launch gmg
testament compani experienc commerci
strategi compani nearli patient
roughli address patient estim
soliri less one year launch despit fact
gmg patient enrol competitor
threat biosimilar loom label expans
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ alexion well-posit withstand
pressur competitor potenti entri earli
biosimilar like entri pnh
expand larger patient popul proactiv
price ultomiri discount offer conveni
dose soliri biosimilar would mean go back
doctor visit per year infus expect
reimburs issu ultomiri biosimilar
usual price discount origin drug
given ultomiri alreadi price discount
offer much conveni dose think like
alexion hold substanti share expect
pipelin ultomiri therapi includ intraven
form offer shorter infus time well weekli
biweekli monthli subcutan self-administ
inject form like bolster patient volum ward
signific ultomiri price headwind
pipelin competitor biosimilar entri pnh
like ahu gmg believ
patent-protect ultomiri label expans orphan
drug indic gmg nmosd help compani
retain moat intang asset support moat
weaken approach end patent protect
market exclus indic
look sever quantit qualit factor
consid moat trend return invest
capit econom profit steadili climb first
five year forecast recov larg
synageva acquisit howev soliri
patent expir signifi substanti weaken
alexion moat sourc intang asset compar
last sever year believ compani merit
neg moat trend wherea alexion narrow moat
cement clear patent protect think
forthcom like biosimilar hit price pressur
indic alexion competit posit
precari next five year compar past
believ strensiq kanuma alexion pipelin
off-set effect soliri biosimilar pipelin
prove promis new data would reconsid
moat trend note despit soliri patent expir
intang asset form compani substanti
experi identifi rare-diseas patient doctor
well mobil special salesforc remain
leverag salesforc patient identif
strategi strengthen econom moat
addit strengthen complement franchis
subcutan pipelin therapi
like way
manag recent built pipelin sinc
compani restructur ad sever candid
rare indic high unmet need
exampl compani ad wilson
diseas promis earli data current
phase trial addit candid includ
warm autoimmun hemolyt anemia waiha
gmg light-chain amyloidosi danicopan
pnh extravascular hemolysi
pnh
complement-medi disord sever drug
preclin develop compani
option co-develop commerci elamipretid
mitochondri diseas thank agreement stealth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
osoliri ultomiri orphan drug statu
strong efficaci garner solid price power rare-
payer market share
oalexion abl leverag rare-diseas
expertis infrastructur effici identifi
patient doctor despit small address
olabel expans gener myasthenia gravi
neuromyel optica spectrum disord drive
oa subcutan competitor could reach market
alexion subcutan version take
soliri ultomiri compani key
ofailur quickli convert patient ultomiri
soliri would leav firm vulner competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
compani strong financi health healthi
balanc sheet portfolio drug provid good cash
gener compani issu billion debt
expens synageva acquisit
leisur pay alexion finish fiscal
billion long-term debt time
adjust ebitda estim compani earn
billion cash flow oper next three
year compani histori return cash
sharehold via stock repurchas expect
continu throughout explicit forecast model
unannounc acquisit possibl see
smaller deal next year manag
team see pipelin candid could good fit
compani
mount pressur competitor
biosimilar relianc soliri ultomiri
expect soliri ultomiri make
total revenu highlight compani potenti
concentr risk one key risk impact
competitor biosimilar although soliri closest
pipelin contend early-stag trial lucr
market size rare autoimmun space like
continu attract competit soliri patent
expir biosimilar could enter pnh market around
endang alexion hold indic
growth ultomiri rare indic offset
hit biosimilar forecast alexion face wide
rang possibl outcom long term launch
competitor molecul conveni method
dose could also captur materi portion soliri
market share alexion pois reach market
better version ultomiri less frequent intraven
dose competit well subcutan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
version regulatori failur could provid window
competitor launch subcutan version
alexion robust clinic program expand soliri
effort
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
fidel manag research compani
new york mellon corp
share
fund
share
fund
new manag record larg unprov
award alexion standard stewardship rate far
believ outlook promis given recent exampl
strong launch gmg approv ultomiri
pipelin acquisit
alexion histor stewardship turbul
result nearli complet leadership turnov throughout
much spur alleg aggress
sale practic subsequ investig
intern investig board audit financ
committe conclud histor financi statement
need restat howev compani soon
reduct addit chang
silver line improp sale probe
experienc execut baxalta merg
shire current alexion ceo ludwig
hantson led baxalta spin-off baxter
spent year novarti johnson johnson
also includ baxalta novarti addit
prior role neurov cfo aradhana sarin
start medic field work sever
major invest bank serv alexion chief
strategi busi offic john orloff head
research develop year experi
biopharmaceut industri includ role baxalta
baxter merck novarti overal despit everyon
rel new tenur alexion bounti experi
give us confid manag team
well-posit lead compani forward
like way manag taken
initi build pipelin ad candid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
hematolog nephrolog metabol diseas neurolog
cardiolog indic reason acquisit
price collabor term still earli judg
new manag acquisit record acquir
asset treat rare diseas high unmet need line
compani core focu strategi sharp
contrast prior manag decis acquir
synageva billion turn
bad bet difficult-to-diagnos metabol diseas
pipelin candid ultim fail
clinic
develop kanuma come synageva
acquisit provid diversif increment
sale firm came steep price
alexion origin founder retir board
director director appoint
board also boast substanti
experi biopharmaceut industri nine
director independ like ceo
chairman role separ chairman david brennan
good fit given experi ceo astrazeneca
brennan led charg briefli compani
turbul period interim ceo
help secur solid current manag team
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
alexion continu exceed expect solid
slightli expect solid progress toward
convert soliri patient next-gener ultomiri
continu pipelin expans cost remain within
reason level total third-quart revenu
billion last year adjust oper
margin improv basi point despit
concern brand biosimilar competit think
narrow-moat alexion well posit hold patient
share four rare ultrarar complement-medi
diseas soliri treat addit seen
pipelin flourish thank acquisit collabor
deal provid addit avenu growth
rare diseas adjust manag rais
full-year guidanc maintain fair valu
estim per share
key question face alexion fare
soliri impend biosimilar threat think alexion
result everi quarter support thesi
next-gener ultomiri conveni
dose offer compel reason patient switch
also think mani patient reluct switch
back less-conveni dose biosimilar enter
market oct elig soliri
patient convert ultomiri mark impress
progress toward compani goal convers
progress germani japan addit ultomiri
recent garner approv second indic atyp
hemolyt urem syndrom ahu allow alexion
switch ahu patient well ahead competit
entri think alexion network patient doctor
support futur commerci effort ultomiri
continu garner approv new indic
importantli even alexion focus ultomiri
convers complement franchis soliri
ultomiri continu see new growth thank soliri
continu penetr gener myasthenia gravi
gmg newli approv neuromyel optica spectrum
disord nmosd third-quart revenu soliri
ultomiri total billion last year
expect two drug earn billion revenu
alexion metabol portfolio perform slightli
expect quarter testament compani
educ effort improv awar diagnosi
ultrarar
hypophosphatasia post million sale
last year driven entir volum growth
kanuma ultrarar lysosom acid lipas defici lal-
contribut million third quarter
last year volum last year
increas full-year estim two drug
million line manag new guidanc
expect continu modest contribut set
therapi ultrarar indic
rare ultrarar
alexion pipelin significantli expand sinc last
year compani current clinic candid
cardiolog other includ preclin compani
develop program across sever asset
repres mark improv time last
year firm hand drug candid outsid
complement franchis like compani focu
rare diseas high unmet need new
therapi significantli impact patient live
command strong price power believ focu
could continu support alexion narrow moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
current assign alexion neg moat trend
believ compani face signific competit
headwind soliri patent expir potenti
entri brand biosimilar competitor howev
see path alexion off-set pipelin
success overal think alexion healthi group
candid sever lucr diseas area variou
stage clinic develop definit
develop call regardless compani
healthi financi posit finish quarter
billion cash equival billion debt
closest catalyst horizon top-lin readout
phase trial danicopan patient paroxysm
hemolysi expect end year anoth
near-term catalyst phase readout stealth
biotherapeut elamipretid primari mitochondri
myopathi pmm expect first quarter next year
remind alexion option co-develop
commerci molecul follow readout
result believ could blockbust
opportun mitochondri diseas
inform soliri biosimilar threat pleas
see aug note amgen challeng alexion soliri
patent sell-off unwarr ultomiri
inform soliri brand competit
pleas see oct note ucb buy ra pharmaceut
billion challeng alexion soliri myasthenia
inform alexion recent acquisit
achillion well option agreement stealth
biotherapeut pleas see oct note alexion
achillion share under-valued
acquisit achillion share under-valued oct
oct narrow-moat alexion announc enter
agreement purchas achillion small biotech
compani focus treatment complement-medi
diseas million roughli million net
cash acquir fund cash hand achillion
pipelin compos danicopan
oral factor inhibitor phase next-
gener factor inhibitor phase addit
per achillion share alexion offer sharehold two
conting valu right one event approv
danicopan one initi phase trial
model adjust acquisit
decreas fair valu estim single-digit
percentag off-set time valu money
sinc last updat maintain fair valu
estim per share stand narrow
moat rate support soliri ultomiri
complement-medi rare ultra-rar diseas
achillion portfolio line alexion core focu
complement-medi diseas util differ
mechan action buy-out also bring potenti
competitor alexion fold see deal
complementari defens danicopan studi
add-on therapi could potenti reduc
amount requir soliri transfus patient
pnh howev ultomiri alreadi offer patient
significantli fewer transfus lower price point
view danicopan substanti threat alexion
plan develop danicopan patient pnh
experienc extravascular hemolysi take
soliri manag indic less
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
patient acquisit materi alter sale
project pnh
howev adjust model add modest revenu
contribut achillion danicopan glomerulopathi
ultra-rar kidney diseas character
progress kidney damag caus overactiv
complement altern pathway approv
treatment option despit support care patient
progress kidney failur face relaps even
kidney transplant affect patient
 approv treatment think area
high unmet need fit well alexion rare-diseas
portfolio earli stage think indic
present blockbust market opportun addit
like alexion portfolio expand address differ
target within complement pathway bolster
competit posit space
note deal manag expect
close first half next year face uncertainti
wait hear regul watch
similar concern rais bristol-celgen
deal result celgen divest otezla
anti-trust concern combin portfolio psoriasi
feder trade commiss action around
bristol acquisit celgen recent delay
roch acquisit spark could see new
pattern tighter scrutini around clinic candid
alexion alreadi domin hold complement-
mediat diseas achillion complement candid
still earli develop respons analyst
question call manag argu achillion
competit
address new group patient pnh patient
patient mostli agre sentiment
still believ deal may face scrutini regul
complementari
alexion acquir candid otherwis could
pose competitor road support neg
moat trend rate think five year
alexion intang asset weaker posit due
expir soliri patent like entri
biosimilar howev seen sign manag
combat competit headwind recent
popul achillion deal compani announc
last week agreement stealth biotherapeut
exclus option co-develop commerci
elamipretid mitochondri diseas step
approv therapi present blockbust
pmm difficult diagnos often misdiagnos
could present constraint commerci
impact size elig popul initi
estim pmm present blockbust opportun
includ estim model unless alexion
exercis option see phase result expect
first half next year
billion
challeng alexion soliri myasthenia gravi
oct ucb announc plan acquir ra
focus
develop therapi complement-medi diseas
transact valu approxim billion net ra
pharma cash ra pharma advanc candid
zilucoplan phase gener myasthenia gravi
gmg rare neuromuscular disord ra pharma one
mani compani includ ucb phase
candid rozanolixizumab hope challeng alexion
entrench posit complement-medi diseas
alexion soliri receiv approv gmg
today soliri approv four differ indic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
later sclerosi al
demonstr broad applic complement
inhibitor ucb hope test zilucoplan sever
indic studi alreadi underway
mediat necrot myopathi like no-moat ucb
build pipelin focus diseas area
high unmet need believ zilucoplan
rozanolixizumab face high degre uncertainti
commerci success approv due alexion first-
adjust model acquisit
maintain fair valu estim eur per share
no-moat rate ucb zilucoplan phase result look
competit efficaci alexion therapi
think ucb would price zilucoplan lower
compet alexion therapi encourag patient
switch howev maintain alexion benefit
first-mov advantag unless compet therapi
significantli effect model peak sale
eur billion candid approv assum
ucb use cash reserv new debt financ
deal ratio net debt adjust ebitda less
time time deal close believ
reason compani
indic confid
ucb expect close deal end first
quarter pend anti-trust approv call
clear
regulatori hurdl howev ucb ra pharma
clinical-stag candid myasthenia gravi
portfolio candid util differ
mechan action may rais anti-trust concern
similar rais bristol celgen roch
spark therapeut believ minor
regulatori risk deal neither compani
candid approv even approv
believ could room competit subset
diseas
amgen challeng alexion soliri patent sell-
unwarr ultomiri potenti aug
narrow-moat alexion receiv disappoint news aug
 patent trial appeal board announc
would institut inter part review ipr evalu
valid three soliri patent issu
would extend patent protect soliri
approv four rare diseas contribut
billion revenu challeng came rival
develop soliri biosimilar could
launch depend valid alexion
patent outcom clinic trial news
ipr took market analyst surpris send
share friday morn believ sell-
unwarr long-term thesi rest alexion
convert patient soliri ultomiri
arsen patent protect maintain
fair valu estim per share continu view
share under-valued howev would surpris
see protract overhang stock given ipr
could last late
analysi assum biosimilar competit paroxysm
nocturn hemoglobinuria
intern think switch patient ultomiri
stymi biosimilar share gain given conveni
dose infus everi two month instead soliri everi
two week slightli lower price notabl alexion
alreadi success switch patient
ultomiri pnh patient switch juli
give us confid project
narrow-moat rate alexion subcutan
version ultomiri success clinic trial
anticip conveni ultomiri inject
incentiv patient doctor treat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
depend clinic outcom
news ipr come roughli week rumor
spanish news sourc would acquir
alexion lift share aug
view takeout rumor low credibl given
develop soliri biosimilar
rumor larg dispel follow week news
purchas otezla celgen
alexion convers ultomiri ahead schedul
oper result total revenu billion
last year soliri approv four rare
diseas contribut million revenu
last year soliri double-digit volum growth off-set
price headwind canada may small
impact rest year metabol drug strensiq
kanuma post double-digit growth
contribut million follow quarter strong
result manag rais guidanc full year
may make adjust model
anticip materi chang fair valu estim
pleas see ultomiri surpass
expect million revenu second
quarter doubl revenu first quarter
manag report paroxysm nocturn
hemoglobinuria pnh patient switch
soliri approach patent expir ultomiri
offer conveni dose schedul everi
two month slightli lower price mean alexion
track well goal convert pnh patient
ultomiri end success patient
convers soliri ultomiri remain key pillar
narrow moat rate believ alexion
abl avoid sever sale declin despit inevit
biosimilar entri patient hesit switch
back soliri inconveni dose schedul everi two
compani sever advanc clinic trial initi
includ phase superior trial
wilson diseas phase trial
warm autoimmun hemolyt anemia
phase trial al amyloidosi
expect research develop cost grow
doubl digit year remain total
revenu medium term
compani announc addit already-
abund pipelin clinic trial plan initi
phase trial ultomiri hematopoiet stem cell
thrombot microangiopathi
hsct-tma seriou complic stem cell transplant
approv treatment option may
off-label use alexion therapi indic
alexion share earli trial result
yet includ model competitor
narsoplimab nomacopan coversin
alreadi trial way hsct-tma alexion
experi clinic develop compar
small competitor suggest compani could catch
quickli expand address patient
popul ultomiri
give littl credit rest alexion pipelin
model point given mani candid still
earli stage includ plan trial
gener myasthenia gravi ultomiri primari
progress multipl sclerosi amyotroph later
sclerosi overal compani focu rare
diseas high unmet need strong price power
see path continu excess return support
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
decis fda ahu octob
see one key risk soliri launch nmosd
diseas difficult diagnos
character recur attack mistaken
disord multipl sclerosi name
suggest nmosd present spectrum mild
sever symptom includ attack weak paralysi
blind howev believ soliri strong launch
gmg testament compani educ
market strategi valuat depend strong
launch intern approv
estim nmosd sale soliri could reach billion
next year
fda approv alexion blockbust drug soliri
 food drug administr soliri
subset patient diagnos neuromyel optica
spectrum disord rare chronic disord brain
spinal cord approv treatment nmosd
fit well alexion strategi target rare indic
high unmet need maintain fair valu
estim per share given posit late-stag
clinic result publish earlier year believ
share look attract
approv provid treatment
posit patient make least two third
total patient popul compani estim
elig patient unit state
significantli expand address popul
soliri current approv ultrarar paroxysm
urem syndrom rare gener myasthenia gravi
given larger popul size estim nmosd
could contribut largest portion revenu
ultrarar price tag sizabl address patient
popul soliri uniqu success stori drawn
competitor space complement-medi
disord includ apelli pharmaceut
finish enrol late-stag trial pnh compar
soliri howev continu believ
expir pnh ahu market exclus gmg
nmosd continu drive excess return
opinion valuat narrow moat rate
depend success launch ultomiri alexion next-
gener therapi conveni dose schedul
ultomiri alreadi approv pnh expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
